386 related articles for article (PubMed ID: 27624182)
1. Manipulation of the host cell membrane by human γ-herpesviruses EBV and KSHV for pathogenesis.
Wei F; Zhu Q; Ding L; Liang Q; Cai Q
Virol Sin; 2016 Oct; 31(5):395-405. PubMed ID: 27624182
[TBL] [Abstract][Full Text] [Related]
2. EBV and KSHV Infection Dysregulates Autophagy to Optimize Viral Replication, Prevent Immune Recognition and Promote Tumorigenesis.
Cirone M
Viruses; 2018 Oct; 10(11):. PubMed ID: 30384495
[TBL] [Abstract][Full Text] [Related]
3. How Epstein-Barr Virus and Kaposi's Sarcoma-Associated Herpesvirus Are Maintained Together to Transform the Same B-Cell.
Sugden AU; Hayes M; Sugden B
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452344
[TBL] [Abstract][Full Text] [Related]
4. Lytic cycle switches of oncogenic human gammaherpesviruses.
Miller G; El-Guindy A; Countryman J; Ye J; Gradoville L
Adv Cancer Res; 2007; 97():81-109. PubMed ID: 17419942
[TBL] [Abstract][Full Text] [Related]
5. Persistent KSHV Infection Increases EBV-Associated Tumor Formation In Vivo via Enhanced EBV Lytic Gene Expression.
McHugh D; Caduff N; Barros MHM; Rämer PC; Raykova A; Murer A; Landtwing V; Quast I; Styles CT; Spohn M; Fowotade A; Delecluse HJ; Papoudou-Bai A; Lee YM; Kim JM; Middeldorp J; Schulz TF; Cesarman E; Zbinden A; Capaul R; White RE; Allday MJ; Niedobitek G; Blackbourn DJ; Grundhoff A; Münz C
Cell Host Microbe; 2017 Jul; 22(1):61-73.e7. PubMed ID: 28704654
[TBL] [Abstract][Full Text] [Related]
6. Nonsense-mediated decay controls the reactivation of the oncogenic herpesviruses EBV and KSHV.
van Gent M; Reich A; Velu SE; Gack MU
PLoS Biol; 2021 Feb; 19(2):e3001097. PubMed ID: 33596193
[TBL] [Abstract][Full Text] [Related]
7. Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells.
Miller G; Heston L; Grogan E; Gradoville L; Rigsby M; Sun R; Shedd D; Kushnaryov VM; Grossberg S; Chang Y
J Virol; 1997 Jan; 71(1):314-24. PubMed ID: 8985352
[TBL] [Abstract][Full Text] [Related]
8. [EBV/KSHV co-infection: an effective partnership].
Gruffat H; Manet E
Med Sci (Paris); 2018 Jan; 34(1):79-82. PubMed ID: 29384100
[TBL] [Abstract][Full Text] [Related]
9. K1 and K15 of Kaposi's Sarcoma-Associated Herpesvirus Are Partial Functional Homologues of Latent Membrane Protein 2A of Epstein-Barr Virus.
Steinbrück L; Gustems M; Medele S; Schulz TF; Lutter D; Hammerschmidt W
J Virol; 2015 Jul; 89(14):7248-61. PubMed ID: 25948739
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas.
Xu D; Coleman T; Zhang J; Fagot A; Kotalik C; Zhao L; Trivedi P; Jones C; Zhang L
J Virol; 2007 Jun; 81(11):6068-78. PubMed ID: 17376914
[TBL] [Abstract][Full Text] [Related]
11. Contribution of the KSHV and EBV lytic cycles to tumourigenesis.
Manners O; Murphy JC; Coleman A; Hughes DJ; Whitehouse A
Curr Opin Virol; 2018 Oct; 32():60-70. PubMed ID: 30268927
[TBL] [Abstract][Full Text] [Related]
12. A pentameric protein ring with novel architecture is required for herpesviral packaging.
Didychuk AL; Gates SN; Gardner MR; Strong LM; Martin A; Glaunsinger BA
Elife; 2021 Feb; 10():. PubMed ID: 33554858
[TBL] [Abstract][Full Text] [Related]
13. The Role of Lytic Infection for Lymphomagenesis of Human γ-Herpesviruses.
Münz C
Front Cell Infect Microbiol; 2021; 11():605258. PubMed ID: 33842383
[TBL] [Abstract][Full Text] [Related]
14. KSHV LANA and EBV LMP1 induce the expression of UCH-L1 following viral transformation.
Bentz GL; Bheda-Malge A; Wang L; Shackelford J; Damania B; Pagano JS
Virology; 2014 Jan; 448():293-302. PubMed ID: 24314660
[TBL] [Abstract][Full Text] [Related]
15. [Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV, HHV-8)].
Katano H
Uirusu; 2010 Dec; 60(2):237-45. PubMed ID: 21488336
[TBL] [Abstract][Full Text] [Related]
16. The oncogenic gamma herpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) hijack retinoic acid-inducible gene I (RIG-I) facilitating both viral and tumour immune evasion.
Nash A; Ryan EJ
Tumour Virus Res; 2022 Dec; 14():200246. PubMed ID: 35998812
[TBL] [Abstract][Full Text] [Related]
17. 25-Hydroxycholesterol Inhibits Kaposi's Sarcoma Herpesvirus and Epstein-Barr Virus Infections and Activates Inflammatory Cytokine Responses.
Serquiña AKP; Tagawa T; Oh D; Mahesh G; Ziegelbauer JM
mBio; 2021 Dec; 12(6):e0290721. PubMed ID: 34781692
[TBL] [Abstract][Full Text] [Related]
18. Chloroquine inhibits lytic replication of Kaposi's sarcoma-associated herpesvirus by disrupting mTOR and p38-MAPK activation.
Yang M; Huang L; Li X; Kuang E
Antiviral Res; 2016 Sep; 133():223-33. PubMed ID: 27521848
[TBL] [Abstract][Full Text] [Related]
19. Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids.
Gorres KL; Daigle D; Mohanram S; Miller G
J Virol; 2014 Jul; 88(14):8028-44. PubMed ID: 24807711
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of Epstein-Barr virus, cytomegalovirus, and Kaposi's sarcoma-associated herpesvirus infections in peripheral blood leukocytes revealed by a multiplex PCR assay.
Nishiwaki M; Fujimuro M; Teishikata Y; Inoue H; Sasajima H; Nakaso K; Nakashima K; Sadanari H; Yamamoto T; Fujiwara Y; Ogawa N; Yokosawa H
J Med Virol; 2006 Dec; 78(12):1635-42. PubMed ID: 17063511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]